Literature DB >> 11936571

Steady-state pharmacokinetics and tolerability of modafinil administered alone or in combination with dextroamphetamine in healthy volunteers.

Edward T Hellriegel1, Sanjay Arora, Michael Nelson, Philmore Robertson.   

Abstract

The potential for a drug-drug interaction between modafinil and dextroamphetamine, each at steady state, was investigated in an open-label, randomized, single-period studyin 32 healthy male and female volunteers. All subjects received modafinil orally once daily for 28 days (200 mg on Days 1-7; 400 mg on Days 8-28). On Days 22 to 28, half of the subjects also received dextroamphetamine (20 mg) orally 7 hours after modafinil. Samples for pharmacokinetic (PK) profiling were obtained on Days 21 and 28. The mean changes in PK parameters for modafinil and its two circulating metabolites between the two groups were not statistically significantly different, except Cmax for modafinil acid. Adverse events obtained in the two groups were similar and mild or moderate in nature. The results indicate that administration of low-dose dextroamphetamine in this dosing regimen does not alter the steady-state pharmacokinetics of modafinil. The combination has a similar tolerability profile as modafinil alone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11936571

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  6 in total

Review 1.  Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder.

Authors:  Georgios Schoretsanitis; Jose de Leon; Chin B Eap; John M Kane; Michael Paulzen
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

2.  Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol.

Authors:  Angela Rowland; Madelé van Dyk; David Warncken; Arduino A Mangoni; Michael J Sorich; Andrew Rowland
Journal:  Br J Clin Pharmacol       Date:  2018-01-10       Impact factor: 4.335

Review 3.  Modafinil : a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder.

Authors:  Gillian M Keating; Michael J Raffin
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  Clinical pharmacokinetic profile of modafinil.

Authors:  Philmore Robertson; Edward T Hellriegel
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 5.  Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management.

Authors:  Henry A Spiller; Hannah L Hays; Alfred Aleguas
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

6.  Optimized Cocktail Phenotyping Study Protocol Using Physiological Based Pharmacokinetic Modeling and In silico Assessment of Metabolic Drug-Drug Interactions Involving Modafinil.

Authors:  Angela Rowland; Arduino A Mangoni; Ashley Hopkins; Michael J Sorich; Andrew Rowland
Journal:  Front Pharmacol       Date:  2016-12-27       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.